Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American brain tumor consortium study

Journal of Clinical Oncology

Volumn 22, Issue 21, 2004, Pages 4282-4289

  Puduvalli, Vinay K ^a   Yung, W K Alfred ^a   Hess, Kenneth R ^a   Kuhn, John G ^a   Groves, Morris D ^a   Levin, Victor A ^a   Zwiebel, James ^a   Chang, Susan M ^a   Cloughesy, Timothy F ^a   Junck, Larry ^a   Wen, Patrick ^a   Lieberman, Frank ^a   Conrad, Charles A ^a   Gilbert, Mark R ^a   Meyers, Christina A ^a   Liu, Vivien ^a   Mehta, Minesh P ^a   Nicholas, M Kelly ^a   Prados, Michael ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; NSC 374551; ANTINEOPLASTIC AGENT;

ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRY SKIN; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; HYPOALBUMINEMIA; MALE; NORTH AMERICA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; ADULT; AGED; BRAIN TUMOR; GLIOMA; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; FENRETINIDE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 14944353655     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.09.096     Document Type: Article

References (30)

1. Walker MD, Strike TA, Sheline GE: An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Intl J Radiat Oncol Biol Phys 5:1725-1731, 1979
2. Lacroix M, Abi-Said D, Fourney DR, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 95:190-198, 2001
3. Stewart LA: Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011-1018, 2002
4. Love JM, Gudas LJ: Vitamin A, differentiation and cancer. Current Opin Cell Biol 6:825-831, 1994
5. Bouterfa H, Picht T, Kess D, et al: Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in established cell lines. Neurosurgery 46:419-430, 2000
6. Yung WK, Kyritsis AP, Gleason MJ, et al: Treatment of malignant gliomas with high dose 13-cis retinoic acid. Clin Cancer Res 2:1931-1935, 1996
7. Decensi A, Formelli F, Torrisi R, et al: Breast cancer chemoprevention: Studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints. J Cell Biochem Suppl 17G: 226-233, 1993
8. De Palo G, Camerini T, Marubini E, et al: Chemoprevention trial of contralateral breast cancer with fenretinide: Rationale, design, methodology, organization, data management, statistics and accrual. Tumori 83:884-894, 1997
9. Pienta KJ, Esper PS, Zwas F, et al: Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. Am J Clin Oncol 20:36-39, 1997
10. Decensi A, Bruno S, Costantini M, et al: Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point. J Natl Cancer Inst 86: 138-140, 1994
11. Sun SY, Yue P, Lotan R: Induction of apoptosis by N-(4-hydroxyphenyl) retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol Pharmacol 55:403-410, 1999
12. Maurer BJ, Metelitsa LS, Seeger RC, et al: Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)retinamide in neuroblastoma cell lines. J Natl Cancer Inst 91:1138-1146, 1999
13. Puduvalli VK, Saito Y, Xu R, et al: Fenretinide activates caspases and induces apoptosis in gliomas. Clin Cancer Res 5:2230-2235, 1999
14. Saitoh Y, Goto T, Puduvalli VK, et al: Induction of apoptosis by N-(4-hydroxyphenyl)retinamide in glioma cells. Int J Oncol 15:499-504, 1999
15. Parchment RE, Jasti BR, Kocarek TA, et al: Pharmacologic issues for fenretinide chemotherapy (4HPR, NSC-374551). Clin Cancer Res Suppl 5:3800s, 1999 (abstr 350)
16. Le Doze F, Debruyne D, Albessard F, et al: Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of rat. Drug Metab Dispos 28:205-208, 2000
17. Cleeland CS, Mendoza TR, Wang XS, et al: Assessing symptom distress in cancer patients: The M.D. Anderson Symptom Inventory. Cancer 89:1634-1646, 2000
18. Doose DR, Minn FL, Stellar S, et al: Effects of meals and meal composition on the bioavailability of fenretinide. J Clin Pharmacol 32:1089-1095, 1992
19. Formelli F, Carsana R, Costa A, et al: Plasma retinol level reduction by the synthetic retinoid fenretinide: A one year follow-up study of breast cancer patients. Cancer Res 49:6149-6152, 1989
20. Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572, 1999
21. Garaventa A, Luksch R, Piccolo MSL, et al: Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9:2032, 2003
22. Formelli F, Clerici M, Campa T, et al: Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 11:2035-2042, 1993
23. Garewal HS, List A, Meyskens F, et al: Phase II trial of fenretinide [N-(4-hydroxyphenyl) retinamide] in myelodysplasia: Possible retinoid-induced disease acceleration. Leuk Res 13:339-343, 1989
24. Caruso RC, Zujewski J, Iwata F, et al: Effects of fenretinide (4-HPR) on dark adaptation. Arch Ophthalmol 116:759-763, 1998
25. Modiano MR, Dalton WS, Lippman SM, et al: Ocular toxic effects of fenretinide. J Natl Cancer Inst 82:1063, 1990
26. Kingston TP, Lowe NJ, Winston J, et al: Visual and cutaneous toxicity which occurs during N-(4-hydroxyphenyl) retinamide therapy for psoriasis. Clin Exp Dermatol 11:624-627, 1986
27. Kaiser-Kupfer MI, Peck GL, Caruso RC, et al: Abnormal retinal function associated with fenretinide, a synthetic retinoid. Arch Ophthalmol 104:69-70, 1986
28. Mehta RG, Moon RC, Hawthorne M, et al: Distribution of fenretinide in the mammary gland of breast cancer patients. Eur J Cancer 27:138-141, 1991
29. Sabichi AL, Modiano MR, Lee JJ, et al: Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. Clin Cancer Res 9:2400-2405, 2003
30. Lang FF, Gilbert MR, Puduvalli VK, et al: Toward better early-phase brain tumor clinical trials: A reappraisal of current methods and proposals for future strategies. Neuro-oncol 4:268-277, 2002